EUR 2.85
(-2.9%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 487.66 Million CAD | 36.66% |
2022 | 356.85 Million CAD | 97.02% |
2021 | 181.12 Million CAD | 117.53% |
2020 | 83.26 Million CAD | 166.07% |
2019 | 31.29 Million CAD | 257.7% |
2018 | 8.74 Million CAD | -12.45% |
2017 | 9.99 Million CAD | 19.77% |
2016 | 8.34 Million CAD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q3 | 131.68 Million CAD | 5.98% |
2024 Q2 | 124.25 Million CAD | -2.97% |
2024 Q1 | 128.06 Million CAD | 0.76% |
2023 Q3 | 124.35 Million CAD | 5.26% |
2023 Q2 | 118.13 Million CAD | 0.05% |
2023 Q1 | 118.07 Million CAD | 9.08% |
2023 FY | 487.66 Million CAD | 36.66% |
2023 Q4 | 127.1 Million CAD | 2.21% |
2022 Q3 | 95.35 Million CAD | 17.68% |
2022 Q1 | 72.21 Million CAD | 34.07% |
2022 Q4 | 108.24 Million CAD | 13.52% |
2022 FY | 356.85 Million CAD | 97.02% |
2022 Q2 | 81.03 Million CAD | 12.2% |
2021 Q1 | 38.31 Million CAD | 42.82% |
2021 Q3 | 48.06 Million CAD | 17.62% |
2021 Q4 | 53.86 Million CAD | 12.06% |
2021 Q2 | 40.86 Million CAD | 6.65% |
2021 FY | 181.12 Million CAD | 117.53% |
2020 FY | 83.26 Million CAD | 166.07% |
2020 Q2 | 19.57 Million CAD | 43.29% |
2020 Q4 | 26.83 Million CAD | 15.63% |
2020 Q1 | 13.65 Million CAD | 19.72% |
2020 Q3 | 23.2 Million CAD | 18.56% |
2019 Q3 | 8.28 Million CAD | 25.65% |
2019 FY | 31.29 Million CAD | 257.7% |
2019 Q4 | 11.4 Million CAD | 37.66% |
2019 Q2 | 6.59 Million CAD | 31.9% |
2019 Q1 | 5 Million CAD | 138.38% |
2018 Q3 | 2.17 Million CAD | 39.96% |
2018 Q2 | 1.55 Million CAD | -43.23% |
2018 FY | 8.74 Million CAD | -12.45% |
2018 Q4 | 2.09 Million CAD | -3.55% |
2018 Q1 | 2.73 Million CAD | 2.35% |
2017 Q3 | 2.92 Million CAD | 0.0% |
2017 Q4 | 2.67 Million CAD | -8.55% |
2017 FY | 9.99 Million CAD | 19.77% |
2016 FY | 8.34 Million CAD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Newron Pharmaceuticals S.p.A. | 9.05 Million EUR | -5284.443% |
Redcare Pharmacy NV | 1.79 Billion EUR | 72.889% |